Cohance Lifesciences Receives Five USFDA Form 483 Observations for Jaggaiahpet API Facility
Cohance Lifesciences Ltd 路 Others (Uncategorized) 路 21 Sept 2026, 5:07 pm
Cohance Lifesciences Receives Five USFDA Form 483 Observations for Jaggaiahpet API Facility The USFDA completed an inspection of Cohance Lifesciences Limited's API manufacturing facility in Jaggaiahpet, Andhra Pradesh, conducted between 14th Sep'26 and 19th Sep'26. The audit concluded with the issuance of a Form FDA 483 with five observations. In response, the company has initiated corrective and preventive actions (CAPA) and plans to submit its formal response to the regulator within the stipulated timeline.
Original exchange filing (PDF)
More announcements from Cohance Lifesciences Ltd
- The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasti Property and Equity Holdings .... 路 12 Nov 2026
- The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasub Property Holdings LLP & Others 路 12 Nov 2026
- Investors Meet 路 11 Nov 2026
- Transcript of Con call 路 11 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasub Property Holdings LLP & Others 路 11 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasti Property and Equity Holdings Pvt Ltd & Others 路 11 Nov 2026
- Investor Presentation 路 07 Nov 2026
- Update on USFDA inspection at Pashamylaram Manufacturing facility. 路 07 Nov 2026
